Stockscreener 앱 받기
2.465
3.71%
-0.095
전일 마감가:
$2.56
열려 있는:
$2.55
하루 거래량:
293.06K
Relative Volume:
0.42
시가총액:
$181.42M
수익:
$6.96M
순이익/손실:
$-46.51M
주가수익비율:
-14.36
EPS:
-0.1716
순현금흐름:
$-37.99M
1주 성능:
+0.61%
1개월 성능:
+36.94%
6개월 성능:
-80.02%
1년 성능:
-86.38%
1일 변동 폭
$2.44
$2.60
1주일 범위
$2.305
$2.649
52주 변동 폭
$1.60
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
명칭
Perspective Therapeutics Inc
전화
509-375-1202
주소
350 Hills Street, Suite 106, Richland
CATX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.465 | 181.42M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
132.13 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.36 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.62 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.46 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.32 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-01 | 개시 | Wedbush | Outperform |
| 2024-09-25 | 개시 | Truist | Buy |
| 2024-07-25 | 개시 | BofA Securities | Buy |
| 2024-05-09 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Perspective Therapeutics Inc (AMEX: CATX): Down -84.76% In 2025, Outlook Remains Negative - Stocksregister
Legal & General Group Plc Has $155,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics to Participate in Upcoming May Investor Conferences - The Manila Times
JPMorgan Chase & Co. Boosts Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Treats First Patient in Phase 1/2a Trial for Solid Tumors - marketscreener.com
Perspective Therapeutics (CATX) Launches Initial Patient Treatme - GuruFocus
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors - The Manila Times
Groundbreaking Cancer Treatment Trial Launches: Perspective's FAP-α Targeted Alpha Therapy Shows Promise - Stock Titan
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of “Buy” by Brokerages - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Perspective Therapeutics Inc (CATX) - Sete News
A company insider recently bought 22,026 shares of Perspective Therapeutics Inc [CATX]. Should You Buy? - knoxdaily.com
Perspective Therapeutics Inc (CATX)’s stock rises to 2.33 per share - uspostnews.com
Perspective Therapeutics Announces Acceptance of VMT-?-NET and V - GuruFocus
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting - The Manila Times
Perspective Therapeutics Announces Acceptance of Key Radiopharmaceutical Data for Presentation at ASCO 2025 Annual Meeting - Nasdaq
Major Breakthrough: Perspective Therapeutics to Present Novel Cancer Treatment Data at ASCO 2025 - Stock Titan
CATX Stock on the Rise: A Promising Investment - investchronicle.com
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR - The Globe and Mail
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results | CATX Stock News - GuruFocus
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results - The Manila Times
Perspective Therapeutics, Inc. to Announce Q1 2025 Financial Results and Business Update on May 12, 2025 - Nasdaq
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial - Bluefield Daily Telegraph
Perspective Therapeutics to Provide Business Highlights and Repo - GuruFocus
Arrowstreet Capital Limited Partnership Has $117,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
KLP Kapitalforvaltning AS Invests $79,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Truist Financial Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - MarketBeat
Perspective Therapeutics (PSTH) Advances Trial for Melanoma Trea - GuruFocus
Perspective Therapeutics Announces First Patient Dosed with [212 - GuruFocus
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy - MarketScreener
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times
Perspective Therapeutics Announces First Patient Dosed With Vmt01 Monotherapy In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - MarketScreener
Breakthrough Melanoma Treatment Shows Promise for Brain Metastasis Patients in Latest Trial - Stock Titan
Is Now The Time To Invest In Perspective Therapeutics (NYSE:CATX) - Seeking Alpha
Perspective Therapeutics (NYSE:CATX) Given New $10.00 Price Target at Truist Financial - Defense World
Truist cuts Perspective Therapeutics target to $10, maintains Buy By Investing.com - Investing.com South Africa
Truist cuts Perspective Therapeutics target to $10, maintains Buy - Investing.com
Paraganglioma Treatment Market Size in 7MM is expected to grow - openPR.com
Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating - marketscreener.com
CATX stock touches 52-week low at $1.87 amid market challenges - Investing.com Australia
CATX stock touches 52-week low at $1.87 amid market challenges By Investing.com - Investing.com South Africa
What is HC Wainwright’s Estimate for CATX Q2 Earnings? - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Analysts - Defense World
Pheochromocytoma Treatment Market Size in 7MM is expected - openPR.com
Pheochromocytomas and Paragangliomas Treatment Market Size - openPR.com
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance
Perspective Therapeutics director Robert Williamson buys $132,151 in stock - Investing.com Australia
Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India
Perspective Therapeutics director Robert Williamson buys $132,151 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock - Investing.com Australia
Perspective Therapeutics director Lori Woods acquires $49,999 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics Inc (CATX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
9.38%
0.17%
자본화:
|
볼륨(24시간):